Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

NDA submitted for breakthrough pain Rx

Nov. 15, 1996

New NK1 antagonists claimed by Takeda

Nov. 15, 1996

Cortech announces further delays in development of Bradycor

Nov. 8, 1996

Taisho discloses agent for cerebrovascular disorders

Nov. 8, 1996

Mitsubishi reports cathepsin B/calpain inhibitors

Nov. 8, 1996

Trophix-Children's Hospital neurodegeneration research collaboration

Nov. 8, 1996

Histamine H3 receptor ligands described by INSERM/Bioprojet

Nov. 8, 1996

Mylan generic drug approved by FDA

Nov. 8, 1996

ImmuLogic's MS therapeutic nearing the clinic

Nov. 8, 1996

FDA approval for Faulding generic anticonvulsant

Nov. 8, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...